ArticleJournal of lipid research2026
Low serum sphingosine-1-phospate and its chaperone ApoM associate with retinopathy of prematurity.
Article in Journal of lipid research, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Retinopathy of prematurity (ROP) is a neurovascular retinal disease affecting extremely preterm infants (<28 weeks' gestational age), and links between early lipid metabolism and ROP are unclear. We investigated whether the lipid mediator sphingosine-1-phosphate (S1P) and its carrier apolipoprotein M (ApoM) are associated with ROP and parenteral nutrition in preterm infants. In this multicenter cohort, extremely preterm infants were grouped by ROP outcome: no ROP (n = 72) or any ROP (n = 105). Serum was collected at birth and longitudinally to postnatal day 100. S1P was quantified by LC-MS/MS and ApoM by proximity extension assay. Associations between first month mean parenteral fluid intake, S1P, ApoM, and ROP were analyzed using logistic regression; log-normal linear regression was applied to continuous outcomes, adjusting for gestational age and LCPUFA supplementation. Results showed that serum S1P and ApoM were positively correlated (r = 0.53, 95% confidence interval [CI] = 0.50-0.56). Higher first-month parenteral fluid intake was associated with lower S1P and ApoM (per 50 ml/kg/day increase, geometric mean ratio = 0.84, 95% CI = 0.79-0.88 for S1P; 0.97, 95% CI = 0.96-0.98 for ApoM; both P < 0.001). Higher mean S1P in the first month was associated with reduced odds of any ROP (per 0.1 μmol/l increase, adjusted odds ratio = 0.84; 95% CI = 0.71-0.99; P = 0.037). Mean ApoM was associated with ROP only in unadjusted analyses. In conclusion, low S1P and ApoM levels were linked to high parenteral fluid exposure and ROP development, suggesting that infants with high parenteral nutrition requirements may be particularly vulnerable to S1P-ApoM depletion, supporting this pathway as a potential therapeutic target.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.